<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>growthbookmark.club / damienbeich2 / Upvoted</title>
<link>http://growthbookmark.club</link>
<description>Your Source for Social News and Networking</description>
<pubDate>Fri, 09 Oct 2026 13:24:46 +0000</pubDate>
<language>en</language>
<item>
	<title><![CDATA[GLP-1 Receptor Agonists Reduce Substance use Disorder: a Role for Addiction to Chemsex Drugs?]]></title>
	<link>http://growthbookmark.club/story.php?title=glp-1-receptor-agonists-reduce-substance-use-disorder-a-role-for-addiction-to-chemsex-drugs</link>
	<source url="http://growthbookmark.club/story.php?title=glp-1-receptor-agonists-reduce-substance-use-disorder-a-role-for-addiction-to-chemsex-drugs"><![CDATA[GLP-1 Receptor Agonists Reduce Substance use Disorder: a Role for Addiction to Chemsex Drugs?]]></source>
	<description><![CDATA[Trulicity▼) are glucagon-like peptide-1 (GLP-1) receptor agonists (also known as GLP-1 mimetic therapies) and are authorised for use in adults with type 2 diabetes to improve glycaemic control, except for Saxenda, which is indicated for weight management. GLP-1 receptor agonists act by stimulating insulin secretion from the pancreas in a glucose-dependent manner, as well as slowing gastric emptying and suppressing glucagon secretion. ]]></description>
	<pubDate>Fri, 09 Oct 2026 13:24:46 +0000</pubDate>
	<author>damienbeich2</author>
	<category>News</category>
	<votes>1</votes>
	<guid>http://growthbookmark.club/story.php?title=glp-1-receptor-agonists-reduce-substance-use-disorder-a-role-for-addiction-to-chemsex-drugs</guid>
</item>

</channel>
</rss>
